Newsbenzinga
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…